Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M131 in Patients With TRBC1-positive Relapsed/Refractory Peripheral T-cell Lymphoma

NCT07758491 is registered in ClinicalTrials.gov with FutureGen Biopharmaceutical (Beijing) Co., Ltd as lead sponsor.

NCT NCT07758491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07758491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M131 in Patients With TRBC1-positive Relapsed/Refractory Peripheral T-cell Lymphoma
Lead sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 30, 2026
Completion date
April 30, 2031
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ctcl, ptcl, trbc1 adc